Kelly Gold appointed to X board as Class II director, joins Audit Committee

X appointed Kelly Gold as a Class II director effective July 1, 2026, and added her to the Audit Committee.Original SEC Filing: X4 Pharmaceuticals, Inc [ XFOR ] - 8-K - Jul. 01, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source…

X appointed Kelly Gold as a Class II director effective July 1, 2026, and added her to the Audit Committee.

IndividualKelly Gold

RoleClass II Director; member, Audit Committee

Type of ChangeAppointed

Effective DateJuly 1, 2026

ReasonNot disclosed

Replacement InfoNot applicable

Background DetailsCurrent CFO of CAMP4 Therapeutics since Apr 2022; former CBO and finance roles at CAMP4 (2017–2022); prior roles at Biogen and Deutsche Bank; BS degrees (Life Sciences & Mechanical Engineering), MBA from MIT Sloan.

Board/Committee Role ChangesJoined Audit Committee; board size increased from five to six directors

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.